Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Galactooligosaccharides (GOS)

Galacto-Oligosaccharides (B-GOS / Bimuno) · also known as GOS, Galacto-oligosaccharides, Human milk oligosaccharide analog, Bimuno

Galactooligosaccharides are fermented by colonic bacteria. In human studies, breath hydrogen rose, which supports fermentation in the gut, and bifidobacteria increased at 15 g/day. Fecal and plasma short-chain fatty acids did not rise noticeably, and there is no direct human evidence for effects on luminal pH or pathogenic bacteria.

Typical dose: For everyday gut microbiota support: 2.5–5 g/day, mixed into a breakfast drink or warm water.
Absorption and forms: GOS dissolves easily in water and tastes slightly sweet. It is stable under acid and heat, so it can be stirred into warm water, coffee or oatmeal. Some products may contain residual lactose or galactose, and tolerance depends on the product and dose. There is no general evidence that it differs from ordinary inulin in how much gas it causes.

Clinical uses and human evidence

Irritable bowel syndrome

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Silk 2009 · Aliment Pharmacol Ther · Randomized crossover trial · n=44 — Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome
  2. Wilson 2020 · Am J Gastroenterol · RCT · n=69 — β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria

Constipation

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Schoemaker 2022 · Nutrients · RCT · n=132 — Prebiotic Galacto-Oligosaccharides Impact Stool Frequency and Fecal Microbiota in Self-Reported Constipated Adults: A Randomized Clinical Trial
  2. Vulevic 2018 · Neurogastroenterol Motil · Randomized crossover trial · n=83 — Effect of a prebiotic galactooligosaccharide mixture (B-GOS®) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence

Diarrhea (including antibiotic-associated diarrhea)

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Hasle 2017 · J Travel Med · RCT · n=523 — Can a galacto-oligosaccharide reduce the risk of traveller's diarrhoea? A placebo-controlled, randomized, double-blind study
  2. Drakoularakou 2010 · Eur J Clin Nutr · RCT · n=159 — A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea

Mechanisms of action

Colonic short-chain fatty acid (SCFA/butyrate) fermentation substrate and receptor activation

★★★★★Mechanism evidence: grade A

Galactooligosaccharides are fermented by several types of colonic bacteria. In human randomized trials, breath hydrogen rose, which supports fermentation in the gut. However, fecal and plasma short-chain fatty acids did not rise noticeably, and there is no direct human evidence that the fermentation products affect luminal pH or pathogenic bacteria.

References (2)
  1. Alles 1999 · Human RCT: GOS was not recovered in feces; breath hydrogen rose in the high-dose group, supporting intestinal fermentation; fecal short-chain fatty acids did not change significantly
  2. Canfora 2017 · Human RCT: 15 g/day GOS increased bifidobacteria, but fecal and plasma short-chain fatty acids did not rise significantly

Secretion of intestinal mucin (MUC2) and the protective mucus gel layer

★★★☆☆Mechanism evidence: grade CSecondary target

In animal studies, galactooligosaccharides can lessen damage to the colonic mucus layer caused by a Western diet. In human cell experiments, they can upregulate MUC2 and other genes in goblet-like cells. It has not been reliably shown, however, that routine supplementation increases goblet cell secretion or mucus thickness in humans.

References (2)
  1. Ghosh 2020 · Mouse study: GOS improved Western diet-induced disruption of the colonic MUC2 mucus layer
  2. Bhatia 2015 · Human cell study: GOS upregulated MUC2 and other genes in goblet-like cells

Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair

★★☆☆☆Mechanism evidence: grade CSecondary target

In animal models of intestinal injury, galactooligosaccharides can upregulate tight junction-related genes such as ZO-1 and occludin. Direct human evidence is insufficient, and changes in inflammatory or stress markers do not prove that tight junctions were repaired.

References (1)
  1. Wang 2021 · Mouse study: GOS improved lipopolysaccharide-induced intestinal injury and upregulated genes such as ZO-1 and occludin

Safety and drug interactions

Contraindicated in severe galactosemia (a rare inherited disease). For people with lactose intolerance, tolerance depends on whether the product contains residual lactose or galactose and on the dose, so no blanket rule applies.
Open in the interactive app ›